ASG Aurora Spine Corporation

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES.


Aurora Spine Corporation  (TSX VENTURE:ASG) ("Aurora Spine" or the "Company") is
pleased to announce that it has completed its previously announced private
placement of common shares ("Common Shares"), pursuant to which the Company
issued 3,173,936 common shares at a price of CDN$3.15 per share for aggregate
gross proceeds of CDN$9,997,898.40 (the "Offering"). The Offering was led by
Clarus Securities Inc. (the "Lead Agent"). 


In connection with the Offering, the Company paid a cash commission to the Lead
Agent equal to 5.5% of the gross proceeds raised under the brokered portion of
the Offering; provided however, that the fee paid in respect of presidents' list
purchasers was 2.0% rather than 5.5%. 


The net proceeds from the Offering will be used to fund manufacturing and sales
and marketing of the Company's ZIP and other FDA approved products and for
general working capital purposes. 


Pursuant to applicable Canadian securities laws, the securities issued on the
date hereof will be subject to a hold period until May 16, 2014. 


The Offering is subject to certain conditions including, but not limited to, the
receipt of all necessary approvals, including the final approval of the TSX
Venture Exchange. 


This news release does not constitute an offer to sell, or a solicitation of an
offer to buy, any of the securities in the United States. The securities have
not been and will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state securities laws and
may not be offered or sold within the United States or to U.S. Persons unless
registered under the U.S. Securities Act and applicable state securities laws or
an exemption from such registration is available.


About Aurora Spine 

Aurora Spine is an early stage company focused on bringing new solutions to the
spinal implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies. 


Forward-Looking Statements 

This news release contains forward-looking information that involves substantial
known and unknown risks and uncertainties, most of which are beyond the control
of Aurora Spine, including, without limitation, those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking information").
Forward-looking information in this news release includes information concerning
the Offering and the proposed use of proceeds of the Offering. Aurora Spine
cautions investors of its securities about important factors that could cause
Aurora Spine's actual results to differ materially from those projected in any
forward-looking statements included in this news release. Any statements that
express, or involve discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and uncertainties which
could cause actual results or outcomes to differ unilaterally from those
expressed in such forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and, accordingly,
prospective investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this press release and
Aurora Spine does not assume any obligation to update or revise them to reflect
new events or circumstances. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004


Aurora Spine Corporation
Eric Fronk
Chief Financial Officer
(760) 424-2004
www.auroraspine.us

Aurora Spine (TSXV:ASG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Aurora Spine (TSXV:ASG)
Gráfica de Acción Histórica
De May 2023 a May 2024